GLP1R and Parkinson disease: Finally, in the light of the promising efficacy of clinically translatable oral doses of sitagliptin in this study, and the preservation of the GLP-1 and GIP receptors across age, and in rodent and human PD, evaluation of sitagliptin is warranted in female 6-OHDA challenged rats, as well as larger animal models.